Comparative effectiveness research (CER) aims to provide patients and physicians with evidence-based guidance on treatment decisions. As researchers conduct CER they face myriad challenges. Although inadequate control of confounding is the most-often cited source of potential bias, selection bias that arises when patients are differentially excluded from analyses is a distinct phenomenon with distinct consequences: confounding bias compromises internal validity, whereas selection bias compromises external validity. Despite this distinction, however, the label "treatment-selection bias" is being used in the CER literature to denote the phenomenon of confounding bias. Motivated by an ongoing study of treatment choice for depression on weight change over time, this paper formally distinguishes selection and confounding bias in CER. By formally distinguishing selection and confounding bias, this paper clarifies important scientific, design, and analysis issues relevant to ensuring validity. First is that the 2 types of biases may arise simultaneously in any given study; even if confounding bias is completely controlled, a study may nevertheless suffer from selection bias so that the results are not generalizable to the patient population of interest. Second is that the statistical methods used to mitigate the 2 biases are themselves distinct; methods developed to control one type of bias should not be expected to address the other. Finally, the control of selection and confounding bias will often require distinct covariate information. Consequently, as researchers plan future studies of comparative effectiveness, care must be taken to ensure that all data elements relevant to both confounding and selection bias are collected. FIGURE 3. A simplified directed acyclic graph for the motivating comparative effectiveness study of treatment for depression (Rx) on a 2-year weight change (Y). Baseline smoking (L 1 ) and weight (L 2 ) are confounders of the association of interest; sex (L 3 ) is associated with weight change but independent of treatment choice. Baseline smoking and sex are determinants of selection into the study subsample but being associated with whether or not a patient has complete data in the EHR. Also shown are various models relevant to the adjustment of confounding bias and selection bias.
C omparative effectiveness research (CER) aims to provide patients and physicians with evidence-based guidance as they make treatment decisions. 1, 2 With the passing of the American Recovery and Reinvestment Act of 2009 and the Patient Protection and Affordable Care Act of 2010, and the recent creation of the Patient-Centered Outcomes Research Institute, 3 CER is a current national priority.
As researchers conduct CER, they face myriad challenges. Chief among these, arguably, is confounding bias which arises when factors that simultaneously affect treatment choice and the outcome are not adequately controlled. This lack of adequate control compromises internal validity, specifically whether or not the observed results reflect causation. 4 A second, distinct challenge is the selection bias that arises when the observed patients are not representative, in some way, of the broader patient population of interest. 5 This lack of representativeness compromises external validity, specifically whether or not results based on a subsample of patients are generalizable. Despite the 2 phenomena being distinct, the labels "confounding bias" and "selection bias" are not always rigorously or appropriately used. The recent Institutes of Medicine report on CER, for example, commented: "y the decision to rely on data from observational studies must be weighed against the possibility of misleading results. The main form of bias (selection bias) occurs when the factors causing a person to experience the intervention are associated with the patient's prognosis." 6 Furthermore, the label "treatment-selection bias" is increasingly being used for the confounding bias in the emerging comparative effectiveness literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] Although this label makes explicit that confounding arises when one fails to adjust for certain factors that affect treatment selection, it increases the potential for confusion between confounding bias and selection bias. Without a clear distinction between the 2 phenomena, however, CER studies run the risk of (i) inadvertently ignoring selection bias, and/or (ii) erroneously believing that statistical methods developed for confounding can be used to adjust for selection bias, and/or (iii) finding that information needed to adequately control for selection bias has not been collected.
Toward mitigating these risks, this paper provides a formal distinction between confounding and selection bias in CER. It also discusses a number of important related issues. Specifically, formally distinguishing confounding and selection bias helps emphasize the distinction across statistical methods used to control the 2 types of bias. This, in turn, has important consequences for study design and the collection of information on patients. Specifically, to adequately control confounding bias, data collection must include all factors that are related to both treatment choice and the outcome of interest; to adequately control selection bias, data collection must include all factors related to why certain patients participate in the study and others do not. The work in this paper was motivated by ongoing CER study of treatment for depression on weight change that is briefly introduced.
CER FOR DEPRESSION TREATMENT
Depression and obesity are major public health concerns. 16, 17 Although the processes underlying their impact on health outcomes are the subjects of much recent research, [18] [19] [20] [21] [22] there is growing evidence that the choice of antidepressant drug therapy influences changes in weight over time. 23, 24 With climbing rates of obesity 17 and antidepressant agents being the most commonly prescribed drugs in the United States, 25 understanding the impact of antidepressant choice on weight change over time is crucial to helping patients and physicians make informed decisions.
Study Setting
We obtained funding from the National Institute of Mental Health to examine this question using data from Group Health, an integrated insurance and health care delivery system serving approximately 650,000 members in western Washington State. As part of its clinical systems, Group Health maintains numerous electronic databases, including an electronic health record (EHR) based on EpicCare (Epic Systems Corporation of Madison, WI) and an electronic pharmacy database with complete prescription information since 1993. Group Health also maintains administrative databases that track demographic data, inpatient treatment and outpatient encounter claims, insurance and enrollment status, and visit appointments.
Data Abstraction
To study the relationship between antidepressant drug therapy and weight change, we considered adults aged 18-65 years with a diagnosis of depressive disorder and who initiated a new monotherapy episode of antidepressant drug treatment. A new monotherapy episode was defined as a dispensing for a single medication without any other antidepressant medication dispensing in the prior 9 months. Restricting to new monotherapy episodes initiated between January 2006 and November 2009, we identified N = 10,606 eligible patients in the Group Health EHR. Data were subsequently abstracted on covariates relevant to the goals of the study. In particular, as the primary outcome of interest is weight change between treatment initiation (baseline), and 2 years later, all weight measurements in the EHR over a 2-year follow-up period were abstracted.
The Potential for Confounding and Selection Bias
As data in the Group Health EHR arise during the course of clinical care, and treatment choices are made within this context, potential confounding is clearly an important consideration. Toward eventually addressing confounding bias, data on all covariates thought to be related to disease severity, comorbid conditions, treatment choice, and weight change were abstracted for all N = 10,606 patients, as well as information on their primary care provider at the time of treatment initiation.
Ideally, all N = 10,606 patients would have complete data in the EHR on all relevant covariates. Perhaps not surprisingly, this was not the case. Crucially, there was substantial missing data on weight: only n = 1637 patients had both baseline and 2-year weight measurements. That complete weight information is missing for n = 8969 of the N = 10,606 patients identified by the inclusion/exclusion criteria questions the representativeness of the subsample and suggests the strong potential for selection bias.
TERMINOLOGY
Informally, addressing the confounding bias and selection bias requires answering 2 key questions. For confounding bias, the relevant question is: why did a patient receive one particular drug over any other?; for selection bias, the relevant question is: why do some patients have complete data and others do not? Towards formalizing these questions, this section introduces terminology that will be used throughout the manuscript. As terminology is defined and elaborated upon, Figure 1 provides an overview of their definitions and the interplay between the various concepts.
The Study Population
A central premise of this paper is the existence of some well-defined patient population of interest, to whom the results are intended to be generalized. Typically, this population is defined by prespecified scientific inclusion/ exclusion criteria, including having been diagnosed with specific disease conditions (eg, by ICD-9 coding) and demographic characteristics (eg, age, sex, race). In addition, researchers often apply further practical inclusion/exclusion criteria. For example, researchers may identify and recruit study participants within some geographic region, from among those who participated in some parent research study (eg, the Nurses' Health Study), from among the members of a health plan (eg, an HMO or the VA), or by enrollment within the Medicare system. Whichever scientific and practical inclusion/exclusion criteria are used, the resulting patient population is referred to as the study population. In the antidepressant study, the study population consists of all adults aged 18-65 years with a diagnosis of depression at Group Health and who initiated a new episode of drug monotherapy between January 2006 and November 2009. On the basis of these criteria, as mentioned above, the resulting study population consisted of N = 10,616 patients.
The Study Subsample
Once the study population is identified, a typical CER study proceeds by selecting patients to be included/recruited and on whom complete data will be collected/abstracted. These patients are referred to as having been selected into the study subsample. In practice, the study subsample may be a random sample from the study population, proactively invited and recruited into the CER study. For CER studies based on an existing, parent research study or on an EHR, proactive patient recruitment may not be necessary and the study subsample could correspond to those patients with complete information on all relevant covariates. In the antidepressant study, the n = 1637 patients with complete weight data (assuming that they have complete information on all other relevant covariates) constitute the study subsample.
Treatment Assignment and Selection Mechanisms
Finally, formally distinguishing confounding and selection bias requires consideration of 2 key mechanisms. The first is the treatment assignment mechanism, which characterizes how patient-level, physician-level, and system-level characteristics influence the decision-making process regarding which treatment any given patient is assigned. The second is the selection mechanism, which characterizes how patient-level, physician-level, and system-level characteristics influence the decision-making process of whether or not a patient in the study population is selected into the study subsample.
CONFOUNDING AND SELECTION BIAS
Consider a comparative effectiveness study of the association between some treatment choice, denoted Rx, and an outcome of interest, denoted Y. In the antidepressant study, Rx is the choice of antidepressant and Y is the 2-year change in weight post-treatment initiation. Assuming a well-defined study population, to formally identify which patients are selected into the study subsample, let S = 0/1 be a binary indicator of observance or selection: individuals selected and whose information is observed have S = 1; individuals not selected and on whom (at least) some information is incomplete have S = 0. In the following, a series of simple directed acyclic graphs (DAGs) are used to formalize confounding and selection bias, 26, 27 to emphasize their distinction from each other and to illustrate that the 2 sources of bias may arise independently and simultaneously.
Confounding Bias
Suppose a randomized trial is conducted to investigate the association between Rx and Y. In addition, suppose patients are prospectively recruited from the study population by random sampling and that information on a collection of pretreatment factors associated with the outcome, denoted by L, is collected. As treatment assignment is random in the trial, estimates based on the study sample can be viewed as representing the causal effect of Rx on Y. That is, randomization guarantees no confounding bias (on average, at least) and internal validity of the study results is ensured. Figure 2A provides a DAG for the randomized trial. That no arrows lead into Rx indicates that treatment assignment is independent of all other factors (ie, it is random). In contrast, Figure 2D provides the DAG for an observational study in which treatment assignment depends on at least 1 component of L. As treatment assignment is not random, confounding bias will arise if one fails to adjust for L in the subsequent analysis and, without appropriate adjustment, internal validity of the study will be compromised.
Structurally, the potential for confounding in Figure 2D is indicated by the arrows that simultaneously emanate from L into both Rx and Y. This structure is also present in Figures 2E and F . Consequently, despite differences with Figure 2D in other parts of their structure, Figures 2E and F also represent studies in which treatment assignment was not random and for which there is the potential for confounding bias.
Selection Bias
Returning to Figure 2A , the presence of "S = 1" in the DAG serves to indicate that the effect of Rx on Y is being investigated solely using information from the study subsample. Specifically, the box around "S = 1" emphasizes that the selection into the study subsample is being conditioned upon. 26, 27 That there are no arrows leading into the boxed "S = 1," however, indicates that mechanism driving selection is independent of Rx, L, and Y; as mentioned above, patients were recruited into the trial by random sampling. As selection is random, the study subsample can be viewed as being representative of study population and the presence of the boxed "S = 1" in the DAG does not compromise the results. That is, random sampling of patients into the study subsample guarantees no selection bias (on average, at least) and external generalizability of the study results to the broader patient population of interest is ensured. Now suppose that the study subsample was not obtained by random sampling and that some nonrandom selection mechanism drove whether or not a patient from the study population is actually in the study subsample. For example, suppose that whether or not a patient decides to participate in the randomized trial, after having been invited, depends on some component of L. Patients with greater pretreatment disease severity may, for example, be less likely to agree to participate. Figure 2B provides a DAG for this setting, with the arrow from L into the boxed "S = 1", representing the dependence of selection on L. As a second example, consider a randomized trial in which patients were initially chosen at random from the study population and all agreed to participate. However, over time some patients drop out before the end of follow-up and the decision to drop out is dependent on their initial treatment assignment and their response to treatment. A study participant may, for example, decide to drop out if they experience some treatment-specific adverse side effect and/or if they do not respond to treatment as hoped. Figure 2C provides a DAG for this setting, with the arrows from Rx and Y into the boxed "S = 1" representing the dependence of the selection mechanism on treatment choice and response.
Structurally, Figures 2B and C share the common feature of having at least 1 arrow leading into the boxed "S = 1." Although the nonrandom selection mechanism differs between the 2 studies (one is a result of differential participation and the other differential drop out), the upshot is the same: the study subsample, on whom complete data are available, is not representative of the study population. In this sense, both studies are subject to potential selection bias and, without appropriate adjustment, external generalizability of the study results will be compromised. Despite this, however, treatment assignment is independent of all other factors in both figures, as evidenced by the lack of an arrow leading into Rx. Consequently, although randomization guarantees internal validity, there is nevertheless the potential for external generalizability to be compromised in both Figures 2B and C.
Simultaneous Confounding and Selection Bias
Finally, consider Figures 2E and F. As mentioned above, both DAGs exhibit the potential for confounding bias because of the arrows simultaneously emanating from L into both Rx and Y. In contrast to Figure 2D , however, the 2 DAGs also indicate the potential for nonrandom selection into the study subsample. Figure 2E represents an observational study with differential participation, whereas Figure 2F represents an observational study with differential drop out. Consequently, Figures 2E and F represent different studies that are simultaneously subject to confounding bias and selection bias. That is, both internal validity and external generalizability are potentially compromised and would both need to be addressed in subsequent analyses.
Statistical Analyses
Although important conceptually, the distinction between confounding and selection bias is also important from the perspective of statistical analyses. To help ground a discussion of these issues, Figure 3 some mechanism that depends on baseline smoking and weight but not sex. Furthermore, whether or not an individual patient has complete data in the EHR (ie, both baseline and 2year weight measurements) is assumed to be dependent on treatment choice, baseline smoking status, and sex. From the discussion in the previous section, the DAG in Figure 3 exhibits structure that is consistent with the study potential being subject to both confounding and selection bias.
Confounding Bias
For the purpose of statistical control of confounding, there is a long history of methodologic research, including recent work that is specific to CER. 28, 29 For the most part, methods fall into one of the 2 general approaches: regression adjustment and propensity score analyses. 30, 31 Regression adjustment relies on building a model for the outcome with treatment choice and potential confounders included in the model specification. For the DAG in Figure 3 , both the "True data model" and the "Regression adjustment model" would suffice for this strategy as (at a minimum) they both include the 2 confounders; as sex is not a confounder, its inclusion in a model for the outcome is unnecessary from the perspective of confounding control, although it will increase statistical efficiency. In contrast to regression adjustment, which relies on a model for the outcome, propensity score analyses rely on a model for the probability of treatment as a function of potential confounders. In Figure 3 , treatment assignment depends solely on baseline smoking and weight; for a binary treatment choice, a logistic regression model such as the one labeled "Propensity model" may be used. Fitted values from this model (ie, predicted probabilities of treatment for any given patient) are referred to as propensity scores, which can then be used in various ways to control confounding bias, including stratification and inverse-probability weighting.
In practice, regression adjustment and propensity score analyses perform equally well in most settings. 30 Crucial to both approaches, however, is that the treatment assignment mechanism is understood. Without this understanding, one would not know which covariates to include in either of the outcome or propensity score models.
Selection Bias
In contrast to the confounding bias, methods specific to selection bias are relatively sparse, particularly in the CER literature. Nevertheless, a useful strategy for the statistical adjustment of selection bias is to view the patients in the study population who were not selected as having missing data. When cast as a missing data problem, selection bias can then be addressed using the broad range of methods developed for more general missing data settings. One such method is multiple imputation. 31, 32 Unfortunately, however, its application in the selection bias context will often be challenging because it involves imputing all information for all patients in the study population who were not selected into the study subsample. A second missing data approach is inverse-probability weighting in which patients who are observed in the study subsample are reweighted in an effort to "reconstruct" the original study population. 32, 33 The weights are taken from the fit of a model that treats whether or not a patient is selected into the subsample as the outcome. For the DAG in Figure 3 , this corresponds to fitting a model for the probability of having complete data in the EHR; the logistic regression labeled "Selection model" provides one possible choice that would ensure that all factors relevant to selection are considered.
Data Considerations
Beyond the control of confounding bias and selection bias requiring the specification of distinct mechanisms/ models, practically, statistical analyses also require fundamentally different data. Specifically, the control of confounding bias requires data on all covariates relevant to the treatment assignment mechanism on all patients in the subsample. That is, the "Regression adjustment model" and/ or the "Propensity model" in Figure 3 would only be fit to those patients with complete data in the EHR (ie, those with S = 1). In contrast, the control of selection bias requires data on all covariates relevant to selection mechanism on all patients in the study population. That is, the "Selection model" in Figure 3 would be fit to all patients in the EHR (ie, those with S = 0 and S = 1).
STUDY DESIGN
That the analysis approaches used to control confounding bias and selection bias require different data has important consequences for study design. As comparative effectiveness studies are developed, submitted for review and funding, considerable attention is typically paid to ensure that all confounders are identified and included in the data collection plan. In the event that data on an important confounder are missing, the study results will suffer from unmeasured confounding bias. In contrast, less emphasis is typically placed on ensuring that all factors involved in the selection process are collected. This may be partly because of the difficult challenge of needing data on these factors for all patients in the study population. In some settings, this information may be readily available. In the antidepressant study, for example, if the patients' age, sex, or concurrent comorbid conditions determine, in part, whether or not a weight measurement is obtained at baseline, this information is available in the EHR. Similarly, if weight measurements are only collected during primary care visits, as opposed to specialty care visits, information in the EHR can be used to identify the visit type, which can then be included in a model for selection. In other settings, however, information relevant to selection may not be available in the EHR. Most problematic for the antidepressant study is that a patient's weight itself may be a determinant of whether or not weight is missing in the EHR, and hence whether or not that particular patient is included in the study subsample. To use the standard missing data nomenclature, this is an informative missingness or missing-not-at-random. 31, 32 Unfortunately, given data in the EHR alone, analyses that attempt to control selection bias would be inadequate and, analogous to unmeasured confounding, residual selection bias would manifest. Resolving this challenge requires additional data collection, beyond the information available in the EHR, specific to the control of selection bias. This is likely to be best achieved through explicit consideration of the selection mechanism and careful planning during the design phase of any given CER study. How to do this efficiently, however, is currently an open methodologic problem.
DISCUSSION
Researchers conducting CER must navigate a wide range of phenomena that result in bias and compromise validity. Unfortunately, the literature is not wholly consistent in the labels used to describe and distinguish these phenomena. The bias that results from inadequate adjustment of a covariate that is simultaneously predictive of treatment and outcome, for example, has been referred to as "confounding bias," "confounding by indication bias," and "treatment-selection bias." Furthermore, as Hernan et al 27 point out, each of the following phenomena/biases can be viewed as being structurally equivalent to selection bias: inappropriate selection of controls in case-control studies, bias differential drop out, volunteer bias, healthy worker bias, and nonresponse bias. That numerous labels are used for the same phenomenon runs the risk of certain biases being overlooked or inadequately handled as studies are designed, conducted, analyzed, and interpreted. In particular, as the control of selection bias and the control of confounding bias use fundamentally different data and statistical analysis approaches, maintaining a formal distinction is essential. Furthermore, as CER matures, new methods will likely need to be developed. Compared with the current trend in research for confounding bias, however, the development of methods for the control of selection bias in CER, including sensitivity analyses, has been sparse at best. Three recent reviews of methods for CER, for example, provided virtually no discussion of selection bias or external validity as a methodologic concern. 29, 34, 35 Confounding bias and selection bias are only 2 of the potential challenges that CER researchers face. Others include misclassification, measurement error and self-report bias, and range of issues specific to the use of large electronic health/administrative databases. 36 With the current emphasis on patient-centered research and personalized medicine, treatment effect heterogeneity has also been identified as an important challenge in CER. [37] [38] [39] In the literature, it is common for studies to report the overall association between treatment choice and outcomes, the so-called main effect. Although this can loosely be interpreted as the average effect across all patients in the population, if the treatment effect is truly heterogenous the overall effect may not be relevant to any given patient. Consequently, treatment effect heterogeneity has implications for generalizability of study results, although this is a distinct phenomenon to the compromised generalizability induced by selection bias. Indeed, external validity of study results, as defined in this paper (ie, the ability to directly translate results from a subsample to the entire patient population), may be compromised regardless of whether or not treatment effects are heterogenous.
CONCLUSIONS
Traditionally, confounding bias has been viewed as the greatest threat to validity of observational CER. Although this may indeed be the case, if study results are to be translatable into clinical practice and, ultimately, useful to patients, researchers must consider all sources of bias. Crucially, consideration needs to be given at the planning and design phase to ensure that researchers have access to all of the information needed to perform statistical adjustments.
